Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934

                                 March 24, 2006
                Date of Report (Date of earliest event reported)

                                 ANTIGENICS INC.
             (Exact name of registrant as specified in its charter)

            DELAWARE                  000-29089               06-1562417
  (State or other jurisdiction       (Commission             (IRS Employer
        of incorporation)            File Number)          Identification No.)

           630 Fifth Avenue, Suite 2100
                New York, NY 10111                               10111
     (Address of principal executive offices)                  (Zip Code)

              (Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities
    Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
    Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

Item 7.01   Regulation FD Disclosure

          On March 24, 2006, Antigenics Inc. announced Phase 3 clinical trial
          results for Oncophage in kidney cancer. The full text of the press
          release issued in connection with the announcement is being furnished
          as Exhibit 99.1 to this current report on Form 8-K.

Item 9.01   Financial Statements and Exhibits

    (d) Exhibits

    The following exhibit is furnished herewith:

        99.1      Press Release dated March 24, 2006


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                                 ANTIGENICS INC.

Date:    March 24, 2006
                                                  By:    /s/ Garo H. Armen, PhD.

                                                            Garo H. Armen, Ph.D.
                                            Chairman and Chief Executive Officer


Exhibit No.       Description of Exhibit
-----------       ----------------------

99.1              Press Release dated March 24, 2006